Lyra Therapeutics, Inc. (LYRA) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	398.0K	398.0K	1.5M	1.6M	1.4M
Cost of Revenue	—	—	—	—	—
Gross Profit	—	—	1.5M	1.6M	1.4M
Operating Expenses
R&D Expense	18.4M	18.4M	43.8M	48.0M	38.8M
SG&A Expense	11.5M	11.5M	18.5M	19.1M	17.6M
General & Admin Expense	11.5M	11.5M	18.5M	19.1M	17.6M
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	1.5M	1.5M	35.6M	1.6M	1.3M
Total Operating Expenses	31.4M	31.4M	97.9M	68.7M	57.7M
Cost and Expenses	—	—	97.9M	68.7M	57.7M
Operating Income (EBIT)	(31.0M)	(31.0M)	(96.3M)	(67.1M)	(56.3M)
Non-Operating
Interest Income	1.1M	1.1M	3.0M	4.5M	1.0M
Interest Expense	—	—	—	—	—
Net Interest Income	—	—	3.0M	4.5M	1.0M
Other Non-Op Income/Expense	2.1M	2.1M	3.0M	4.5M	1.0M
Non-Operating Income (excl Interest)	(2.2M)	—	(35.6M)	(1.6M)	(1.3M)
EBT (Pre-Tax Income)	(28.9M)	(28.9M)	(93.4M)	(62.6M)	(55.3M)
Income Tax Expense	(11.0K)	(11.0K)	39.0K	59.0K	13.0K
Bottom Line
Net Income	(28.9M)	(28.9M)	(93.4M)	(62.7M)	(55.3M)
Earnings from Cont. Ops	(28.9M)	(28.9M)	(93.4M)	(62.7M)	(55.3M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(28.9M)	(28.9M)	(93.4M)	(62.7M)	(55.3M)
Per Share
Basic EPS	($18.62)	($18.62)	($1.43)	($1.26)	($1.83)
Diluted EPS	($18.62)	($18.62)	($1.43)	($1.26)	($1.83)
Revenue Per Share	$0.03	$0.03	$0.02	$0.03	$0.05
Shares
Basic Shares Outstanding	15.5M	15.5M	65.1M	49.7M	30.2M
Diluted Shares Outstanding	15.5M	15.5M	65.1M	49.8M	30.2M
Profitability Metrics
EBITDA	(31.0M)	(31.0M)	(60.3M)	(65.3M)	(53.9M)
D&A	—	—	471.0K	278.0K	1.1M
EBIT	—	—	(60.7M)	(65.5M)	(55.0M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025